David G Harrison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2090214/publications.pdf

Version: 2024-02-01

178 papers 27,515 citations

7568 77 h-index 153 g-index

203 all docs

203 docs citations

times ranked

203

23729 citing authors

#	Article	IF	CITATIONS
1	Innate immunity and clinical hypertension. Journal of Human Hypertension, 2022, 36, 503-509.	2.2	20
2	IL-17A is associated with flow-mediated dilation and IL-4 with carotid plaque in persons with HIV. Aids, 2022, Publish Ahead of Print, .	2.2	5
3	A Message to the Hypertension Community Regarding the Ukraine Crisis. Hypertension, 2022, , .	2.7	1
4	Tissue Sodium in Patients With Early Stage Hypertension: A Randomized Controlled Trial. Journal of the American Heart Association, 2022, 11, e022723.	3.7	7
5	Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus. JCI Insight, 2022, 7, .	5.0	15
6	Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. Journal of Clinical Investigation, 2022, 132, .	8.2	11
7	IsoLGs (Isolevuglandins) Drive Neutrophil Migration in Hypertension and Are Essential for the Formation of Neutrophil Extracellular Traps. Hypertension, 2022, 79, 1644-1655.	2.7	7
8	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research, 2021, 117, 29-42.	3.8	164
9	Sodium activates human monocytes via the NADPH oxidase and isolevuglandin formation. Cardiovascular Research, 2021, 117, 1358-1371.	3.8	41
10	Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction. Circulation, 2021, 143, 1242-1255.	1.6	33
11	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	2.2	29
12	Anticytomegalovirus CD4 + T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1459-1473.	2.4	7
13	Pathophysiology of Hypertension. Circulation Research, 2021, 128, 847-863.	4.5	112
14	Deacetylation mimetic of mitochondrial cyclophilin D CypDâ€K166R mutant mice are protected from inflammation, oxidative stress, endothelial dysfunction and hypertension. FASEB Journal, 2021, 35, .	0.5	0
15	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
16	Growth Arrest Specific-6 and Axl Coordinate Inflammation and Hypertension. Circulation Research, 2021, 129, 975-991.	4.5	19
17	Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by sodium-23 magnetic resonance imaging. Nephrology Dialysis Transplantation, 2021, 36, 1307-1317.	0.7	27
18	Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovascular Research, 2021, 117, 2589-2609.	3.8	25

#	Article	IF	CITATIONS
19	New insight sheds light as to how nitrite might reduce blood pressure height: is this alright?. Cardiovascular Research, 2020, 116 , $1-3$.	3.8	3
20	Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions., 2020, 205, 107418.		27
21	Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress. Circulation Research, 2020, 126, 439-452.	4.5	195
22	E-vaporating benefits of e-vaping. European Heart Journal, 2020, 41, 2484-2486.	2.2	4
23	Effects of Interleukin- $1\hat{l}^2$ Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk. Hypertension, 2020, 75, 477-482.	2.7	69
24	Mitochondrial Isolevuglandins Contribute to Vascular Oxidative Stress and Mitochondria-Targeted Scavenger of Isolevuglandins Reduces Mitochondrial Dysfunction and Hypertension. Hypertension, 2020, 76, 1980-1991.	2.7	17
25	Hypertension and osteoporosis: Common pathophysiological mechanisms. Medicine in Novel Technology and Devices, 2020, 8, 100047.	1.6	5
26	Highly Reactive Isolevuglandins Promote Atrial Fibrillation Caused by Hypertension. JACC Basic To Translational Science, 2020, 5, 602-615.	4.1	17
27	From Rags to Riches. Hypertension, 2020, 75, 930-934.	2.7	13
28	Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension. Hypertension, 2020, 75, 902-917.	2.7	24
29	Inflammation in Hypertension. Canadian Journal of Cardiology, 2020, 36, 635-647.	1.7	194
30	Sympathetic Enhancement of Memory T-Cell Homing and Hypertension Sensitization. Circulation Research, 2020, 126, 708-721.	4.5	23
31	A New Look At the Mosaic Theory of Hypertension. Canadian Journal of Cardiology, 2020, 36, 591-592.	1.7	5
32	A T-Cell Small RNA With miRacle Effects on Aortic Stiffening. Circulation Research, 2020, 126, 1004-1006.	4.5	2
33	High Salt Activates CD11c ⁺ Antigen-Presenting Cells via SGK (Serum Glucocorticoid) Tj ETQq1 1 0 555-563.	.784314 r _ş 2.7	gBT /Overloc 94
34	Central EP3 (E Prostanoid 3) Receptors Mediate Salt-Sensitive Hypertension and Immune Activation. Hypertension, 2019, 74, 1507-1515.	2.7	15
35	Solving Baroreceptor Mystery: Role of PIEZO Ion Channels. Journal of the American Society of Nephrology: JASN, 2019, 30, 911-913.	6.1	14
36	Scientists on the Spot: Inflammation and translational researchâ€"what have we learned from the CIRT trial?. Cardiovascular Research, 2019, 115, e44-e45.	3.8	3

#	Article	IF	CITATIONS
37	Markers or Makers. Hypertension, 2019, 73, 767-769.	2.7	12
38	Th1â€type immune responses to <i>Porphyromonas gingivalis</i> antigens exacerbate angiotensin IIâ€dependent hypertension and vascular dysfunction. British Journal of Pharmacology, 2019, 176, 1922-1931.	5.4	35
39	Ronald G. Victor. Hypertension, 2019, 73, 13-14.	2.7	О
40	Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction, and enhances hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H639-H646.	3.2	116
41	NOX5 as a therapeutic target in cerebral ischemic injury. Journal of Clinical Investigation, 2019, 129, 1530-1532.	8.2	12
42	Mitochondrial Deacetylase Sirt3 as a New Target in Cardiovascular Diseases. FASEB Journal, 2019, 33, 693.1.	0.5	0
43	Serum Glucocorticoid Kinase 1 (SGK1) Expression in Dendritic Cells Contributes to Saltâ€Induced Hypertension in Mice. FASEB Journal, 2019, 33, 861.1.	0.5	0
44	The nerve of the spleen! Causing hypertension by placental growth factor. Cardiovascular Research, 2018, 114, 356-357.	3.8	0
45	Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance. Neuro-Oncology, 2018, 20, 1055-1067.	1.2	27
46	Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease. Hypertension, 2018, 71, e1-e8.	2.7	224
47	The immunology of hypertension. Journal of Experimental Medicine, 2018, 215, 21-33.	8.5	286
48	What matters in Cardiovascular Research? Scientific discovery driving clinical delivery. Cardiovascular Research, 2018, 114, 1565-1568.	3.8	10
49	Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovascular Research, 2018, 114, 1547-1563.	3.8	121
50	Nocturnal noise knocks NOS by Nox: mechanisms underlying cardiovascular dysfunction in response to noise pollution. European Heart Journal, 2018, 39, 3540-3542.	2.2	4
51	Oxidative stress induces BH4 deficiency in male, but not female, SHR. Bioscience Reports, 2018, 38, .	2.4	11
52	Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight, 2018, 3, .	5.0	60
53	The Role of Salt, Serum Glucocorticoid Kinase 1, and NADPH Oxidase in Saltâ€ S ensitive Hypertension. FASEB Journal, 2018, 32, 718.18.	0.5	0
54	High Salt Promotes Human Monocytes Activation In Vitro and In Vivo. FASEB Journal, 2018, 32, 718.17.	0.5	0

#	Article	IF	Citations
55	Loss of Salt Sensing Kinase, SGK1, in T cells abrogates Memory Cell Formation, Hypertension and Endâ€Organ Damage. FASEB Journal, 2018, 32, 870.1.	0.5	O
56	Sympathetic Innervation Promotes Bone Marrow Homing of Specific CD8 + Effector Memory T Cells in Hypertension. FASEB Journal, 2018, 32, 918.1.	0.5	0
57	CD70 Modulates the Role of eNOS In Endothelial Cells. FASEB Journal, 2018, 32, 845.7.	0.5	1
58	Do high-salt microenvironments drive hypertensive inflammation?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R1-R4.	1.8	25
59	High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation. Journal of Clinical Investigation, 2017, 127, 1944-1959.	8.2	153
60	Peer-Based Anatomy Tutoring for First-Year Medical Students: an Analysis of Peer-Tutoring from the Tutors' Perspective. Medical Science Educator, 2017, 27, 57-61.	1.5	2
61	Dendritic Cell Amiloride-Sensitive Channels Mediate Sodium-Induced Inflammation and Hypertension. Cell Reports, 2017, 21, 1009-1020.	6.4	185
62	A New Role of Mister (MR) T in Hypertension. Circulation Research, 2017, 120, 1527-1529.	4.5	10
63	Sirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension. Circulation Research, 2017, 121, 564-574.	4.5	195
64	Oxidative Stress and Hypertensive Diseases. Medical Clinics of North America, 2017, 101, 169-193.	2.5	122
65	Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIV. AIDS Research and Human Retroviruses, 2017, 33, 181-186.	1.1	32
66	The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovascular Research, 2017, 113, 1009-1023.	3.8	302
67	A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage. JCI Insight, 2017, 2, .	5.0	86
68	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. Journal of Clinical Investigation, 2017, 127, 2725-2738.	8.2	75
69	Mitochondrial Cyclophilin D in Vascular Oxidative Stress and Hypertension. Hypertension, 2016, 67, 1218-1227.	2.7	65
70	Is Hypertension a Bone Marrow Disease?. Circulation, 2016, 134, 1369-1372.	1.6	11
71	BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction. Circulation Research, 2016, 119, 434-449.	4.5	40
72	Activation of Human T Cells in Hypertension. Hypertension, 2016, 68, 123-132.	2.7	191

#	Article	IF	Citations
73	Novel methods for microCT-based analyses of vasculature in the renal cortex reveal a loss of perfusable arterioles and glomeruli in eNOS-/- mice. BMC Nephrology, 2016, 17, 24.	1.8	33
74	CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli. Circulation Research, 2016, 118, 1233-1243.	4.5	128
75	Excessive Adventitial Remodeling Leads to Early Aortic Maladaptation in Angiotensin-Induced Hypertension. Hypertension, 2016, 67, 890-896.	2.7	93
76	Central Artery Stiffness in Hypertension and Aging. Circulation Research, 2016, 118, 379-381.	4.5	137
77	Role of chemokine RANTES in the regulation of perivascular inflammation, Tâ€cell accumulation, and vascular dysfunction in hypertension. FASEB Journal, 2016, 30, 1987-1999.	0.5	185
78	The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. Journal of Experimental Medicine, 2016, 213, 337-354.	8.5	403
79	Origin of Matrix-Producing Cells That Contribute to Aortic Fibrosis in Hypertension. Hypertension, 2016, 67, 461-468.	2.7	65
80	Immune Mechanisms in Arterial Hypertension. Journal of the American Society of Nephrology: JASN, 2016, 27, 677-686.	6.1	157
81	Renal Denervation Prevents Immune Cell Activation and Renal Inflammation in Angiotensin Il–Induced Hypertension. Circulation Research, 2015, 117, 547-557.	4.5	189
82	Memories that last in hypertension. American Journal of Physiology - Renal Physiology, 2015, 308, F1197-F1199.	2.7	31
83	Renal Transporter Activation During Angiotensin-II Hypertension is Blunted in Interferon-Î ³ ^{â°'/â°'} and Interleukin-17A ^{â°'/â°'} Mice. Hypertension, 2015, 65, 569-576.	2.7	166
84	Inflammation, Immunity, and Hypertensive End-Organ Damage. Circulation Research, 2015, 116, 1022-1033.	4.5	554
85	Phage-Display-Guided Nanocarrier Targeting to Atheroprone Vasculature. ACS Nano, 2015, 9, 4435-4446.	14.6	27
86	Integrative network analysis reveals molecular mechanisms of blood pressure regulation. Molecular Systems Biology, 2015, 11, 799.	7.2	102
87	Myeloid Suppressor Cells Accumulate and Regulate Blood Pressure in Hypertension. Circulation Research, 2015, 117, 858-869.	4.5	73
88	Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. Journal of Clinical Investigation, 2015, 125, 1189-1202.	8.2	128
89	Immune activation caused by vascular oxidation promotes fibrosis and hypertension. Journal of Clinical Investigation, 2015, 126, 50-67.	8.2	170
90	GTP Cyclohydrolase I Gene Polymorphisms Are Associated with Endothelial Dysfunction and Oxidative Stress in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e108587.	2.5	11

#	Article	IF	Citations
91	Inflammation and Mechanical Stretch Promote Aortic Stiffening in Hypertension Through Activation of p38 Mitogen-Activated Protein Kinase. Circulation Research, 2014, 114, 616-625.	4.5	200
92	Nox2-Induced Production of Mitochondrial Superoxide in Angiotensin II-Mediated Endothelial Oxidative Stress and Hypertension. Antioxidants and Redox Signaling, 2014, 20, 281-294.	5.4	248
93	Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L868-L876.	2.9	38
94	Oligoclonal CD8 ⁺ T Cells Play a Critical Role in the Development of Hypertension. Hypertension, 2014, 64, 1108-1115.	2.7	185
95	Basic science. Journal of the American Society of Hypertension, 2014, 8, 601-603.	2.3	10
96	Role of Vascular Oxidative Stress in Obesity and Metabolic Syndrome. Diabetes, 2014, 63, 2344-2355.	0.6	116
97	DC isoketal-modified proteins activate T cells and promote hypertension. Journal of Clinical Investigation, 2014, 124, 4642-4656.	8.2	400
98	The Mosaic Theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. Journal of the American Society of Hypertension, 2013, 7, 68-74.	2.3	74
99	Role of the NADPH Oxidases in the Subfornical Organ in Angiotensin II–Induced Hypertension. Hypertension, 2013, 61, 382-387.	2.7	95
100	Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. Journal of Clinical Investigation, 2013, 123, 2803-2815.	8.2	338
101	Mitochondrial superoxide in proâ€hypertensive Tâ€cell activation. FASEB Journal, 2013, 27, 906.8.	0.5	1
102	Thick Ascending Limbâ€Specific NOS1 Knockout Reduces Urinary Osmolality in Type 1 Diabetes. FASEB Journal, 2013, 27, 910.12.	0.5	0
103	Blunted hypertensive response to Ang II infusion in IFNâ€g knockout mice: molecular mechanisms. FASEB Journal, 2013, 27, 906.12.	0.5	0
104	The role of central memory CD8 T cells in the kidney and the role of these cells in genesis of hypertension. FASEB Journal, 2013, 27, 905.7.	0.5	0
105	Lymphocyteâ€specific adaptor protein, LNK, inhibits angiotensin Ilâ€induced hypertension and inflammation. FASEB Journal, 2013, 27, 708.15.	0.5	0
106	Renal denervation prevents renal T cell activation in mice during angiotensin IIâ€induced hypertension. FASEB Journal, 2013, 27, lb696.	0.5	0
107	Stressâ€dependent hypertension and the role of T lymphocytes. Experimental Physiology, 2012, 97, 1161-1167.	2.0	30
108	Vascular Inflammatory Cells in Hypertension. Frontiers in Physiology, 2012, 3, 128.	2.8	146

#	Article	IF	CITATIONS
109	T Lymphocytes and Vascular Inflammation Contribute to Stress-Dependent Hypertension. Biological Psychiatry, 2012, 71, 774-782.	1.3	78
110	Alterations of T cell receptor $\hat{Vl^2}$ chain usage in angiotensin llinduced hypertension. FASEB Journal, 2012, 26, 879.3.	0.5	0
111	Rapid and Specific Measurements of Superoxide Using Fluorescence Spectroscopy. FASEB Journal, 2012, 26, 578.3.	0.5	2
112	Creating of GTP Cyclohydrolaseâ€1 Knock in Mouse. FASEB Journal, 2012, 26, lb642.	0.5	0
113	Inflammation, Immunity, and Hypertension. Hypertension, 2011, 57, 132-140.	2.7	718
114	Tetrahydrobiopterin Deficiency and Nitric Oxide Synthase Uncoupling Contribute to Atherosclerosis Induced by Disturbed Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1547-1554.	2.4	50
115	Role of Increased Guanosine Triphosphate Cyclohydrolase-1 Expression and Tetrahydrobiopterin Levels upon T Cell Activation. Journal of Biological Chemistry, 2011, 286, 13846-13851.	3.4	27
116	Interleukin 17 Promotes Angiotensin II–Induced Hypertension and Vascular Dysfunction. Hypertension, 2010, 55, 500-507.	2.7	662
117	Inhibition and Genetic Ablation of the B7/CD28 T-Cell Costimulation Axis Prevents Experimental Hypertension. Circulation, 2010, 122, 2529-2537.	1.6	249
118	Induction of Hypertension and Peripheral Inflammation by Reduction of Extracellular Superoxide Dismutase in the Central Nervous System. Hypertension, 2010, 55, 277-283.	2.7	154
119	Central and Peripheral Mechanisms of T-Lymphocyte Activation and Vascular Inflammation Produced by Angiotensin Il–Induced Hypertension. Circulation Research, 2010, 107, 263-270.	4.5	280
120	Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H673-H679.	3.2	157
121	Regulation of Endothelial Cell Tetrahydrobiopterin. Advances in Pharmacology, 2010, 60, 107-132.	2.0	35
122	Role of the adaptive immune system in hypertension. Current Opinion in Pharmacology, 2010, 10, 203-207.	3.5	137
123	Therapeutic Targeting of Mitochondrial Superoxide in Hypertension. Circulation Research, 2010, 107, 106-116.	4.5	639
124	Inhibition of T cell Costimulation Prevents the Development of Hypertension. FASEB Journal, 2010, 24, 983.1.	0.5	0
125	Monitoring GTPCH†Interaction with GFRP Using Timeâ€Resolved Fluorescence Resonance Energy Transfer. FASEB Journal, 2010, 24, 871.3.	0.5	0
126	Interleukin 17 promotes atherosclerosis and protects against aneurysmal rupture. FASEB Journal, 2010, 24, 589.8.	0.5	0

#	Article	IF	CITATIONS
127	Oral Tetrahydrobiopterin Treatment Prevents Accelerated Atherosclerosis Caused by Oscillatory Shear Stress. FASEB Journal, 2010, 24, lb565.	0.5	0
128	Superoxide production in the medullary thick ascending limb modulates blood pressure. FASEB Journal, 2010, 24, 792.5.	0.5	0
129	Stimulation of GTP Cyclohydrolase I by Phosphorylation Upon T Cell Activation. FASEB Journal, 2010, 24, lb187.	0.5	0
130	Oxidative Stress and Hypertension. Medical Clinics of North America, 2009, 93, 621-635.	2. 5	285
131	Is hypertension an immunologic disease?. Current Cardiology Reports, 2008, 10, 464-469.	2.9	72
132	Enhanced Hype. American Journal of Cardiology, 2008, 102, 368-369.	1.6	5
133	Calcium-Dependent NOX5 Nicotinamide Adenine Dinucleotide Phosphate Oxidase Contributes to Vascular Oxidative Stress in Human Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 52, 1803-1809.	2.8	249
134	Molecular Mechanisms of Angiotensin II–Mediated Mitochondrial Dysfunction. Circulation Research, 2008, 102, 488-496.	4.5	616
135	Importance of the chemokine RANTES in the development of angiotensin IIâ€induced hypertension and vascular dysfunction. FASEB Journal, 2008, 22, 1210.8.	0.5	0
136	Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction. Journal of Experimental Medicine, 2007, 204, 2449-2460.	8.5	1,468
137	Role of the Multidrug Resistance Protein-1 in Hypertension and Vascular Dysfunction Caused by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 762-768.	2.4	86
138	Oxidative stress and hypertension. Journal of the American Society of Hypertension, 2007, 1, 30-44.	2.3	97
139	Measurement of Reactive Oxygen Species in Cardiovascular Studies. Hypertension, 2007, 49, 717-727.	2.7	457
140	Bone Morphogenic Protein-4 Induces Hypertension in Mice. Circulation, 2006, 113, 2818-2825.	1.6	117
141	Endothelial deficiency of sepiapterin reductase in hypertension and its impact on sepiapterin as an eNOSâ€recoupling agent. FASEB Journal, 2006, 20, A652.	0.5	0
142	Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H37-H42.	3.2	90
143	Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H7-H12.	3.2	77
144	The Role of the Multidrug Resistance Protein-1 in Modulation of Endothelial Cell Oxidative Stress. Circulation Research, 2005, 97, 637-644.	4.5	114

#	Article	IF	CITATIONS
145	Redox Mechanisms in Blood Vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 274-278.	2.4	309
146	Can vitamin E prevent cardiovascular events and cancer?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 510-511.	3.3	12
147	Endothelial control of vasomotion and nitric oxide production. Cardiology Clinics, 2003, 21, 289-302.	2.2	58
148	The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends in Pharmacological Sciences, 2003, 24, 471-478.	8.7	627
149	Akt-Dependent Phosphorylation of Serine 1179 and Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Cooperatively Mediate Activation of the Endothelial Nitric-Oxide Synthase by Hydrogen Peroxide. Molecular Pharmacology, 2003, 63, 325-331.	2.3	178
150	Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation, 2003, 111, 1201-1209.	8.2	678
151	Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation, 2003, 111, 1201-1209.	8.2	1,284
152	Role of p47 ^{<i>phox</i>} in Vascular Oxidative Stress and Hypertension Caused by Angiotensin II. Hypertension, 2002, 40, 511-515.	2.7	533
153	NAD(P)H Oxidase-derived Hydrogen Peroxide Mediates Endothelial Nitric Oxide Production in Response to Angiotensin II. Journal of Biological Chemistry, 2002, 277, 48311-48317.	3.4	164
154	Diabetes Mellitus Enhances Vascular Matrix Metalloproteinase Activity. Circulation Research, 2001, 88, 1291-1298.	4.5	438
155	Oxidative stress and vascular damage in hypertension. Coronary Artery Disease, 2001, 12, 455-461.	0.7	92
156	Induction of Endothelial NO Synthase by Hydrogen Peroxide via a Ca ²⁺ /Calmodulin-Dependent Protein Kinase II/Janus Kinase 2–Dependent Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1571-1576.	2.4	145
157	Dysfunctional Regulation of Endothelial Nitric Oxide Synthase (eNOS) Expression in Response to Exercise in Mice Lacking One eNOS Gene. Circulation, 2001, 103, 2839-2844.	1.6	132
158	Endothelial Regulation of Vasomotion in ApoE-Deficient Mice. Circulation, 2001, 103, 1282-1288.	1.6	683
159	Oxidant Stress as a Marker for Cardiovascular Events. Circulation, 2001, 104, 2638-2640.	1.6	97
160	Out, damned dot: studies of the NAD(P)H oxidase in atherosclerosis. Journal of Clinical Investigation, 2001, 108, 1423-1424.	8.2	44
161	Transcriptional and Posttranscriptional Regulation of Endothelial Nitric Oxide Synthase Expression by Hydrogen Peroxide. Circulation Research, 2000, 86, 347-354.	4.5	383
162	Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. Circulation Research, 2000, 87, 840-844.	4.5	3,329

#	Article	IF	Citations
163	Increased Superoxide in Heart Failure. Circulation, 1999, 100, 216-218.	1.6	152
164	Dual Role of Reactive Oxygen Species in Vascular Growth. Circulation Research, 1999, 85, 562-563.	4.5	138
165	Superoxide Production, Risk Factors, and Endothelium-Dependent Relaxations in Human Internal Mammary Arteries. Circulation, 1999, 99, 53-59.	1.6	98
166	Posttranscriptional Regulation of Endothelial Nitric Oxide Synthase During Cell Growth. Circulation Research, 1999, 85, 588-595.	4.5	72
167	Evidence for a Causal Role of the Renin-Angiotensin System in Nitrate Tolerance. Circulation, 1999, 99, 3181-3187.	1.6	96
168	Reactive oxygen species and the control of vasomotor tone. Current Hypertension Reports, 1999, 1, 102-108.	3.5	37
169	Role of NADH/NADPH Oxidase–Derived H ₂ O ₂ in Angiotensin Il–Induced Vascular Hypertrophy. Hypertension, 1998, 32, 488-495.	2.7	592
170	Endothelial Function and Oxidant Stress. Clinical Cardiology, 1997, 20, II-11.	1.8	168
171	Expression of Multiple Isoforms of Nitric Oxide Synthase in Normal and Atherosclerotic Vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2479-2488.	2.4	426
172	Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. Journal of Molecular Medicine, 1997, 75, 891-900.	3.9	61
173	Role of Superoxide in Angiotensin Il–Induced but Not Catecholamine-Induced Hypertension. Circulation, 1997, 95, 588-593.	1.6	647
174	p22phox mRNA Expression and NADPH Oxidase Activity Are Increased in Aortas From Hypertensive Rats. Circulation Research, 1997, 80, 45-51.	4.5	423
175	Modulation of Endothelial Cell Nitric Oxide Synthase Expression. Japanese Circulation Journal, 1996, 60, 815-821.	1.0	15
176	Effects of shear on endothelial cell calcium in the presence and absence of ATP. FASEB Journal, 1995, 9, 968-973.	0.5	61
177	Molecular Regulation of the Bovine Endothelial Cell Nitric Oxide Synthase by Transforming Growth Factor $\hat{a} \in \hat{a}$ (sub>1. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1255-1261.	2.4	168
178	Dendritic Cell Amiloride Sensitive Channels Mediate Sodium-induced Inflammation and Hypertension. SSRN Electronic Journal, 0, , .	0.4	0